JP2017509628A5 - - Google Patents

Download PDF

Info

Publication number
JP2017509628A5
JP2017509628A5 JP2016556898A JP2016556898A JP2017509628A5 JP 2017509628 A5 JP2017509628 A5 JP 2017509628A5 JP 2016556898 A JP2016556898 A JP 2016556898A JP 2016556898 A JP2016556898 A JP 2016556898A JP 2017509628 A5 JP2017509628 A5 JP 2017509628A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
insr
disorder
variant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016556898A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017509628A (ja
JP6712230B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/019362 external-priority patent/WO2015138278A1/en
Publication of JP2017509628A publication Critical patent/JP2017509628A/ja
Publication of JP2017509628A5 publication Critical patent/JP2017509628A5/ja
Application granted granted Critical
Publication of JP6712230B2 publication Critical patent/JP6712230B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016556898A 2014-03-11 2015-03-09 リポジストロフィーおよびインスリン産生の欠損またはインスリンシグナル伝達の欠損と関連する代謝性障害を処置する方法 Active JP6712230B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461950960P 2014-03-11 2014-03-11
US61/950,960 2014-03-11
PCT/US2015/019362 WO2015138278A1 (en) 2014-03-11 2015-03-09 Methods of treating metabolic disorders associated with lipodystrophies and defects in insulin production or signaling

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020094831A Division JP2020147583A (ja) 2014-03-11 2020-05-29 リポジストロフィーおよびインスリン産生の欠損またはインスリンシグナル伝達の欠損と関連する代謝性障害を処置する方法

Publications (3)

Publication Number Publication Date
JP2017509628A JP2017509628A (ja) 2017-04-06
JP2017509628A5 true JP2017509628A5 (https=) 2018-04-05
JP6712230B2 JP6712230B2 (ja) 2020-06-17

Family

ID=52682963

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016556898A Active JP6712230B2 (ja) 2014-03-11 2015-03-09 リポジストロフィーおよびインスリン産生の欠損またはインスリンシグナル伝達の欠損と関連する代謝性障害を処置する方法
JP2020094831A Pending JP2020147583A (ja) 2014-03-11 2020-05-29 リポジストロフィーおよびインスリン産生の欠損またはインスリンシグナル伝達の欠損と関連する代謝性障害を処置する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020094831A Pending JP2020147583A (ja) 2014-03-11 2020-05-29 リポジストロフィーおよびインスリン産生の欠損またはインスリンシグナル伝達の欠損と関連する代謝性障害を処置する方法

Country Status (4)

Country Link
US (3) US20170065678A1 (https=)
EP (1) EP3125921B1 (https=)
JP (2) JP6712230B2 (https=)
WO (1) WO2015138278A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY34346A (es) 2011-09-26 2013-04-30 Novartis Ag Proteínas de fusión para tratar trastornos metabólicos
TW201315742A (zh) 2011-09-26 2013-04-16 Novartis Ag 治療代謝病症之雙功能蛋白質
AU2018297285A1 (en) 2017-07-06 2020-01-30 Yale University Compositions and methods for treating or preventing endocrine FGF-linked diseases
US20200376080A1 (en) 2017-12-22 2020-12-03 Novartis Ag Methods of treating metabolic disorders with fgf21 variants
EP3586860A1 (en) * 2018-06-22 2020-01-01 Universität Ulm Complement inhibitors and uses thereof
CN109836486B (zh) * 2019-01-30 2020-09-08 北京双因生物科技有限公司 成纤维生长因子21变体、其融合蛋白及其用途

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7459540B1 (en) 1999-09-07 2008-12-02 Amgen Inc. Fibroblast growth factor-like polypeptides
CA2490261A1 (en) * 2002-06-27 2004-01-08 The University Of Queensland Differentiation modulating agents and uses therefor
MXPA05013565A (es) 2003-06-12 2006-03-09 Lilly Co Eli Proteinas de fusion analogas al glp-1.
US20070253966A1 (en) 2003-06-12 2007-11-01 Eli Lilly And Company Fusion Proteins
US7504506B2 (en) * 2003-11-04 2009-03-17 Elixir Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
CN1890371A (zh) 2003-12-10 2007-01-03 伊莱利利公司 成纤维细胞生长因子的21突变蛋白
CA2552404A1 (en) * 2004-01-29 2005-08-18 Applied Research Systems Ars Holding N.V. Methods and compositions for the treatment of lipodystrophy
SI1751184T1 (sl) 2004-05-13 2010-01-29 Lilly Co Eli Fgf-21 fuzijski proteini
US20080176790A1 (en) 2004-10-29 2008-07-24 Defrees Shawn Remodeling and Glycopegylation of Fibroblast Growth Factor (Fgf)
CA2682147C (en) 2007-03-30 2017-08-08 Ambrx, Inc. Modified fgf-21 polypeptides and their uses
CA2693504A1 (en) 2007-08-03 2009-02-12 Eli Lilly And Company Treatment for obesity
US20110015345A1 (en) 2008-03-19 2011-01-20 Ambrx, Inc. Modified FGF-23 Polypeptides and Their Uses
EP2296690B1 (en) 2008-06-04 2016-11-30 Amgen, Inc Fgf21 mutants and uses thereof
JP5878757B2 (ja) 2008-10-10 2016-03-08 アムジエン・インコーポレーテツド Ｆｇｆ２１変異体およびその使用
BRPI1007313A2 (pt) 2009-01-23 2016-02-10 Novo Nordisk As derivados de fgf21 com ligante de albumina a-b-c-d-e e seu uso.
EP2427207B1 (en) 2009-05-05 2017-08-16 Amgen, Inc Fgf21 mutants and uses thereof
HRP20240135T1 (hr) 2009-05-05 2024-04-12 Amgen Inc. Fgf21 mutanti i njihove upotrebe
WO2011154349A2 (en) 2010-06-08 2011-12-15 Novo Nordisk A/S Fgf21 analogues and derivatives
MX368790B (es) 2009-10-15 2019-10-16 Genentech Inc Factores de crecimiento de fibroblasto quimericos con especificidad de receptor alterada.
UA109888C2 (uk) 2009-12-07 2015-10-26 ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
EP2460527A1 (en) 2010-01-21 2012-06-06 Sanofi Pharmaceutical composition for treating a metabolic syndrome
ES2543634T3 (es) 2010-01-22 2015-08-20 Novo Nordisk A/S Proceso para preparación de FGF-21 con grado de O-glicosilación bajo
CA2796055A1 (en) 2010-04-15 2011-10-20 Amgen Inc. Human fgf receptor and .beta.-klotho binding proteins
EP2595647A1 (en) 2010-07-20 2013-05-29 Novo Nordisk A/S N-terminal modified fgf21 compounds
WO2012040518A2 (en) 2010-09-22 2012-03-29 Amgen Inc. Carrier immunoglobulins and uses thereof
JP2014500248A (ja) 2010-11-05 2014-01-09 コヴェックス・テクノロジーズ・アイルランド・リミテッド 抗糖尿病化合物
US9023791B2 (en) * 2010-11-19 2015-05-05 Novartis Ag Fibroblast growth factor 21 mutations
EP2392927A1 (en) * 2011-03-11 2011-12-07 F. Hoffmann-La Roche AG Diagnosis of metabolic disorders in HIV infected patients
WO2012177481A2 (en) 2011-06-24 2012-12-27 University Of Miami Fibroblast growth factor receptor inhibition for the treatment of disease
WO2013006486A2 (en) 2011-07-01 2013-01-10 Ngm Biopharmaceuticals, Inc. Compositions, uses and methods for treatment of metabolic disorders and diseases
EP2548570A1 (en) 2011-07-19 2013-01-23 Sanofi Pharmaceutical composition for treating a metabolic syndrome
MX2014002260A (es) * 2011-08-31 2014-08-18 Amgen Inc Factor de crecimiento de fibroblasto 21 para usar en el tratamiento de diabetes tipo 1.
UY34346A (es) * 2011-09-26 2013-04-30 Novartis Ag Proteínas de fusión para tratar trastornos metabólicos
TW201315742A (zh) * 2011-09-26 2013-04-16 Novartis Ag 治療代謝病症之雙功能蛋白質
AR087973A1 (es) * 2011-10-04 2014-04-30 Lilly Co Eli Variantes del factor 21 del crecimiento de fibroblastos
TWI513705B (zh) 2012-06-11 2015-12-21 Lilly Co Eli 纖維母細胞生長因子２１蛋白質
TW201420606A (zh) 2012-08-22 2014-06-01 Lilly Co Eli 同源二聚體蛋白
WO2014037373A1 (en) 2012-09-07 2014-03-13 Sanofi Fusion proteins for treating a metabolic syndrome
HK1214832A1 (zh) 2012-11-28 2016-08-05 恩格姆生物制药公司 用於代謝病症和疾病治療的組合物和方法
MX383664B (es) 2012-12-27 2025-03-14 Ngm Biopharmaceuticals Inc Uso de un péptido para modular la homeostasis de los ácidos biliares o tratamiento de una enfermedad relacionada con los ácidos biliares.
WO2014149699A1 (en) 2013-03-15 2014-09-25 Eli Lilly And Company Bifunctional protein
CA2943355C (en) 2014-03-25 2023-09-05 Regeneron Pharmaceuticals, Inc. Fgf21 receptor agonists and uses thereof
US10398758B2 (en) 2014-05-28 2019-09-03 Ngm Biopharmaceuticals, Inc. Compositions comprising variants of FGF19 polypeptides and uses thereof for the treatment of hyperglycemic conditions
WO2015195509A2 (en) 2014-06-16 2015-12-23 Ngm Biopharmaceuticals, Inc. Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
WO2016048999A2 (en) 2014-09-23 2016-03-31 Salk Institute For Biological Studies Fgf21 truncations and mutants and uses thereof
SMT202100388T1 (it) 2014-10-24 2021-09-14 Bristol Myers Squibb Co Polipeptidi fgf-21 modificati e loro usi

Similar Documents

Publication Publication Date Title
JP2017509628A5 (https=)
GT201600263A (es) Ácidos grasos novedosos y su uso en la conjugación con biomoléculas
JP6379300B2 (ja) ＧＬＰ及び免疫グロブリンハイブリッドＦｃ融合ポリペプチド及びその用途
HRP20211575T1 (hr) Fuzijski proteini za liječenje metaboličkih poremećaja
Hassan et al. Evolution and clinical translation of drug delivery nanomaterials
JP2014526441A5 (https=)
JP2017519739A5 (https=)
JP2018507914A5 (https=)
WO2013009545A8 (en) Engineered polypeptides having enhanced duration of action with reduced immunogenicity
JP2014500880A5 (https=)
JP2016532690A5 (https=)
AR083920A1 (es) Metodos de tratamiento de trastornos asociados con el fgf21 (factor de crecimiento de fibroblastos 21)
JP2014530220A5 (https=)
BR112014032526A2 (pt) composto, e composição farmacêutica
WO2016060517A3 (ko) 신규한 3-(4- (벤질옥시)페닐)핵스- 4-이노익 산 유도체 및 다른 유효 성분을 포함하는 대사성 질환의 예방 또는 치료용 복합제제
BR112013030067A2 (pt) "conjugado polipeptídico, composição farmacêutica compreendendo o referido conjugado e uso do mesmo"
WO2016109823A8 (en) Treatment of pediatric growth hormone deficiency with human growth hormone analogues
RU2010113994A (ru) Применение панкреатического полипептида человека в качестве терапевтического средства
JP2010500284A5 (https=)
MX2022007929A (es) Coagonistas de triazol grapados de los receptores de glucagon y glp-1.
JP2017514829A5 (https=)
Maksimov et al. Possibilities of placentary medicine in restoration treatment
Ghofrani et al. Efficacy and safety of macitentan for inoperable chronic thromboembolic pulmonary hypertension: results from the randomized controlled MERIT study
JP2020040998A5 (https=)
BR112022012335A2 (pt) Peptídeo, composição, métodos para tratar um paciente e para tratar uma doença, e, uso de um peptídeo